Koers Oasmia Pharmaceutical AB NORDIC GROWTH MARKET
Aandelen
OASM
SE0000722365
Farmaceutische producten
Omzet 2022 | 3,04 mln. 282K 260K | Omzet 2023 | 6,61 mln. 613K 566K | Marktkapitalisatie | 219 mln. 20,33 mln. 18,78 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -357 mln. -33,11 mln. -30,58 mln. | Nettowinst (verlies) 2023 | -129 mln. -11,96 mln. -11,05 mln. | EV/omzet 2022 | 32,6 x |
Nettoliquiditeiten 2022 | 134 mln. 12,46 mln. 11,51 mln. | Nettoliquiditeiten 2023 | 77,04 mln. 7,15 mln. 6,6 mln. | EV/omzet 2023 | 21,5 x |
K/w-verhouding 2022 |
-0,6
x | K/w-verhouding 2023 |
-1,7
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 61,42% |
Recentste transcriptie over Oasmia Pharmaceutical AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-23 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 01-12-20 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-03-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 44 | 19-03-19 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 26-09-19 |
Pål Ryfors
BRD | Director/Board Member | 41 | 25-05-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,30% | 588 mld. | |
-3,42% | 364 mld. | |
+18,02% | 326 mld. | |
+4,27% | 285 mld. | |
+14,79% | 239 mld. | |
+9,66% | 210 mld. | |
-7,48% | 200 mld. | |
+8,12% | 167 mld. | |
-1,42% | 161 mld. |